IBDEI0GU ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7828,0)
 ;;=435.9^^35^477^107
 ;;^UTILITY(U,$J,358.3,7828,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7828,1,4,0)
 ;;=4^435.9
 ;;^UTILITY(U,$J,358.3,7828,1,5,0)
 ;;=5^Transient Ischemic Attack
 ;;^UTILITY(U,$J,358.3,7828,2)
 ;;=^21635
 ;;^UTILITY(U,$J,358.3,7829,0)
 ;;=354.2^^35^477^109
 ;;^UTILITY(U,$J,358.3,7829,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7829,1,4,0)
 ;;=4^354.2
 ;;^UTILITY(U,$J,358.3,7829,1,5,0)
 ;;=5^Ulnar Nerve Entrapment
 ;;^UTILITY(U,$J,358.3,7829,2)
 ;;=^268506
 ;;^UTILITY(U,$J,358.3,7830,0)
 ;;=729.1^^35^477^35
 ;;^UTILITY(U,$J,358.3,7830,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7830,1,4,0)
 ;;=4^729.1
 ;;^UTILITY(U,$J,358.3,7830,1,5,0)
 ;;=5^Fibromyalgia
 ;;^UTILITY(U,$J,358.3,7830,2)
 ;;=Fibromyalgia^80160
 ;;^UTILITY(U,$J,358.3,7831,0)
 ;;=438.20^^35^477^11
 ;;^UTILITY(U,$J,358.3,7831,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7831,1,4,0)
 ;;=4^438.20
 ;;^UTILITY(U,$J,358.3,7831,1,5,0)
 ;;=5^CVA w/Hemiplegia (late effect)
 ;;^UTILITY(U,$J,358.3,7831,2)
 ;;=CVA w/Hemiplegia^317910
 ;;^UTILITY(U,$J,358.3,7832,0)
 ;;=438.12^^35^477^8
 ;;^UTILITY(U,$J,358.3,7832,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7832,1,4,0)
 ;;=4^438.12
 ;;^UTILITY(U,$J,358.3,7832,1,5,0)
 ;;=5^CVA w/Dysphasia (late effect)
 ;;^UTILITY(U,$J,358.3,7832,2)
 ;;=Stroke w/Dysphasia^317908
 ;;^UTILITY(U,$J,358.3,7833,0)
 ;;=356.8^^35^477^90
 ;;^UTILITY(U,$J,358.3,7833,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7833,1,4,0)
 ;;=4^356.8
 ;;^UTILITY(U,$J,358.3,7833,1,5,0)
 ;;=5^Peripheral Neuropathy, Idiopathic
 ;;^UTILITY(U,$J,358.3,7833,2)
 ;;=Peripheral Neuropathy, Idio^268525
 ;;^UTILITY(U,$J,358.3,7834,0)
 ;;=337.20^^35^477^100
 ;;^UTILITY(U,$J,358.3,7834,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7834,1,4,0)
 ;;=4^337.20
 ;;^UTILITY(U,$J,358.3,7834,1,5,0)
 ;;=5^Reflexive Sympathetic Dystrophy
 ;;^UTILITY(U,$J,358.3,7834,2)
 ;;=Reflexive Sympathetic Dystrophy^295799
 ;;^UTILITY(U,$J,358.3,7835,0)
 ;;=294.8^^35^477^33
 ;;^UTILITY(U,$J,358.3,7835,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7835,1,4,0)
 ;;=4^294.8
 ;;^UTILITY(U,$J,358.3,7835,1,5,0)
 ;;=5^Dementia, Other
 ;;^UTILITY(U,$J,358.3,7835,2)
 ;;=^268044
 ;;^UTILITY(U,$J,358.3,7836,0)
 ;;=438.6^^35^477^7
 ;;^UTILITY(U,$J,358.3,7836,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7836,1,4,0)
 ;;=4^438.6
 ;;^UTILITY(U,$J,358.3,7836,1,5,0)
 ;;=5^CVA w/Dysesthesia (late effect)
 ;;^UTILITY(U,$J,358.3,7836,2)
 ;;=CVA w/Dysesthesia (late effect)^328503
 ;;^UTILITY(U,$J,358.3,7837,0)
 ;;=438.7^^35^477^26
 ;;^UTILITY(U,$J,358.3,7837,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7837,1,4,0)
 ;;=4^438.7
 ;;^UTILITY(U,$J,358.3,7837,1,5,0)
 ;;=5^CVA w/Vision Changes (late effect)
 ;;^UTILITY(U,$J,358.3,7837,2)
 ;;=CVA w/Vision Changes (late effect)^328504
 ;;^UTILITY(U,$J,358.3,7838,0)
 ;;=438.84^^35^477^5
 ;;^UTILITY(U,$J,358.3,7838,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7838,1,4,0)
 ;;=4^438.84
 ;;^UTILITY(U,$J,358.3,7838,1,5,0)
 ;;=5^CVA w/Ataxia (late effect)
 ;;^UTILITY(U,$J,358.3,7838,2)
 ;;=CVA w/Ataxia (late effect)^328507
 ;;^UTILITY(U,$J,358.3,7839,0)
 ;;=434.91^^35^477^27
 ;;^UTILITY(U,$J,358.3,7839,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7839,1,4,0)
 ;;=4^434.91
 ;;^UTILITY(U,$J,358.3,7839,1,5,0)
 ;;=5^CVA, Acute Onset
 ;;^UTILITY(U,$J,358.3,7839,2)
 ;;=^295738
 ;;^UTILITY(U,$J,358.3,7840,0)
 ;;=333.94^^35^477^101
 ;;^UTILITY(U,$J,358.3,7840,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,7840,1,4,0)
 ;;=4^333.94
 ;;^UTILITY(U,$J,358.3,7840,1,5,0)
 ;;=5^Restless Leg Syndrome
 ;;^UTILITY(U,$J,358.3,7840,2)
 ;;=^105368
 ;;
 ;;$END ROU IBDEI0GU
